*Disclaimer

NEUROTECH INTERNATIONAL LIMITED (ASX: NTI)

๐Ÿ”— ๐Ÿ“„ ๐Ÿ“ˆ

NTI: NTI Receives HREC Approval for Rett Syndrome Clinical Trial

NEUROTECH INTERNATIONAL LIMITED

2023-07-10 09:17:00

NTI: NTI Granted 2 Year Extension of Treatment for ASD Patients

NEUROTECH INTERNATIONAL LIMITED

2023-05-31 09:22:00

NTI: NTI granted HREC Approval for PANDAS/PANS Trial Extension

NEUROTECH INTERNATIONAL LIMITED

2023-05-30 09:23:00

NTI: NTI Completes Recruitment in PANDAS/PANS Clinical Trial

NEUROTECH INTERNATIONAL LIMITED

2023-05-03 09:11:00

NTI: NTI to Launch Phase II Clinical Trial in Rett Syndrome

NEUROTECH INTERNATIONAL LIMITED

2023-03-20 09:03:00

NTI: Phase I/II ASD Clinical Trials Results at 52 Weeks

NEUROTECH INTERNATIONAL LIMITED

2023-03-17 09:45:00

NTI: First Patient Treated in Phase I/II PANDAS/PANS Trial

NEUROTECH INTERNATIONAL LIMITED

2023-02-16 11:27:00

NTI: Approval for Additional Phase I/II ASD Trial Extension

NEUROTECH INTERNATIONAL LIMITED

2023-02-14 10:11:00

NTI: HREC Approval for Phase I/II PANDAS/PANS Clinical Trial

NEUROTECH INTERNATIONAL LIMITED

2023-01-27 09:33:00

NTI: NTI Granted FDA Pre-IND Meeting for NTI164 in ASD

NEUROTECH INTERNATIONAL LIMITED

2023-01-19 11:30:00